Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01829477 · ClinicalTrials.gov registry record · Phase 3
Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 3
- Development phase
- 33
- Enrollment target
NCT01829477 is a Phase 3 study that was terminated before completion, run by Takeda. The registered enrollment target is 33 participants.
The verdict
NCT01829477, a Phase 3 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of TAK-875 compared to placebo on glycemic control over a 24-week Treatment Period when used as an add-on to glimepiride in addition to diet and exercise.
Interventions
- DRUG Glimepiride
- DRUG TAK-875
- DRUG TAK-875 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01829477
The ClinicalTrials.gov registry entry for NCT01829477 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Glimepiride is the first listed.
NCT01829477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01829477 about?
NCT01829477 is a clinical study titled "Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes". The purpose of this study is to evaluate the effect of TAK-875 compared to placebo on glycemic control over a 24-week Treatment Period when used as an add-on to glimepiride in addition to diet and exercise.
What is the current status of trial NCT01829477?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 33 participants. The study started on 2013-04. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01829477?
The interventions under investigation include: Glimepiride (DRUG), TAK-875 (DRUG), TAK-875 Placebo (DRUG).
Who is sponsoring clinical trial NCT01829477?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.